JP Morgan Reinstates Overweight on Insmed, Announces $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has reinstated Insmed (NASDAQ:INSM) with an Overweight rating and set a price target of $36.

November 20, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Insmed has been reinstated by JP Morgan with an Overweight rating and a price target of $36, indicating a positive outlook for the stock.
Analyst ratings, especially from major banks like JP Morgan, can significantly influence investor sentiment and stock prices. The Overweight rating suggests that JP Morgan believes INSM will outperform the market or its sector, and the $36 price target implies a potential upside from the current trading price. This could lead to increased investor interest and a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100